Today shareholders of XBiotech Inc (NASDAQ:XBIT) received more good news about the company’s Phase III European Trial of Xilonix in Colorectal Cancer. New data from the trial has indicated that secondary measures of antibody activity were improved.
John Simard, CEO of XBiotech Inc (NASDAQ:XBIT), stated, “We believe this study serves as a confirmation that Xilonix is a unique anti-cancer agent for gently treating advanced, even fragile cancer patients. We are also very proud that the study represents a milestone in the development of new clinical endpoints to assess efficacy of novel treatments that help heal patients with advanced disease.”
Xilonix, which is a human antibody therapeutic, appears to be a novel treatment for advanced colorectal cancer. XBiotech Inc (NASDAQ:XBIT) believes that these secondary findings go a long way in corroborating the therapeutic value of Xilonix. Shares are $1.51 or 17.32 in early morning trading today. The stock closed at $8.72 during the last trading session. It is down 54.84% since June 4, 2015 and is downtrending. It has underperformed the S&P500 by 50.15%.
XBiotech Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $280.65 million. The Firm is engaged in discovering and developing True Humanmonoclonal antibodies for treating various diseases. It currently has negative earnings. The Firm focuses to develop MABp1, a therapeutic antibody, which specifically neutralizes interleukin-1 alpha .